Predicting clinical outcomes in people with NAFLD: no need for a crystal ball?

[1]  V. Wong,et al.  Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. , 2023, The lancet. Gastroenterology & hepatology.

[2]  A. Sanyal,et al.  Non-invasive assessment of liver fibrosis in NAFLD. , 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  P. Valery,et al.  An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care , 2022, Diabetic medicine : a journal of the British Diabetic Association.

[4]  C. Canivet,et al.  Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events , 2022, Journal of Hepatology.

[5]  S. McPhail,et al.  Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics , 2020, Hepatology communications.

[6]  H. Razavi,et al.  Nonalcoholic fatty liver disease burden: Australia, 2019–2030 , 2020, Journal of gastroenterology and hepatology.

[7]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[8]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[9]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[10]  G. Garas,et al.  Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma , 2017, Hepatology communications.